Agilent Technologies, Inc. (A) Return on Equity (ROE): 19.85%
Is Agilent Technologies, Inc.’s return on equity (ROE) high or low?
Agilent Technologies, Inc.'s return on equity (ROE) of 19.85% is in line with its 5-year average of 20.54%, around the middle of its 5-year range (14.75%–23.64%).
The return on equity (ROE) for Agilent Technologies, Inc. (A) is 19.85% as of Wednesday, June 10, 2026. It is below its 12-month average by 3.59% (20.59%).
A Return on Equity (ROE) Chart
A Average Return on Equity (ROE) Chart
A Current vs Average Return on Equity (ROE) Chart
A Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
19.85%
RETURN ON EQUITY (ROE) AVG TTM
20.59%
RETURN ON EQUITY (ROE) AVG 3Y
21.51%
RETURN ON EQUITY (ROE) AVG 5Y
20.54%
RETURN ON EQUITY (ROE) AVG 10Y
17.03%
RETURN ON EQUITY (ROE) AVG 15Y
17.40%
RETURN ON EQUITY (ROE) AVG 20Y
19.91%
CURRENT VS TTM AVG
-3.59%
CURRENT VS 3Y AVG
-7.71%
CURRENT VS 5Y AVG
-3.35%
CURRENT VS 10Y AVG
+16.53%
CURRENT VS 15Y AVG
+14.09%
CURRENT VS 20Y AVG
-0.29%
A Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Agilent Technologies, Inc. (A) | — | 19.85% | 20.59% | 21.51% | 20.54% |
| Zoetis Inc. (ZTS) | $34.20B | 81.75% | 66.19% | 56.82% | 52.60% |
| Centene Corporation (CNC) | $31.94B | -30.07% | -10.46% | -1.37% | 1.10% |
| IQVIA Holdings Inc. (IQV) | $30.60B | 22.26% | 21.77% | 21.17% | 17.55% |
| Humana Inc. (HUM) | $43.78B | 6.08% | 7.05% | 11.93% | 15.09% |
| IDEXX Laboratories, Inc. (IDXX) | $44.47B | 70.38% | 60.82% | 72.53% | 81.69% |
| DexCom, Inc. (DXCM) | $29.24B | 31.47% | 28.93% | 25.01% | 22.95% |
| Biogen Inc. (BIIB) | $29.00B | 7.36% | 8.42% | 11.86% | 16.52% |
| Veeva Systems Inc. (VEEV) | $26.73B | 12.89% | 12.42% | 12.32% | 13.45% |
| Waters Corporation (WAT) | $23.83B | 2.94% | 29.98% | 64.02% | 111.55% |
Return Analysis
ROE
19.9%
ROA
10.8%
Agilent Technologies, Inc. Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Agilent Technologies, Inc. Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for Agilent Technologies, Inc. (A)?
- The return on equity (ROE) for A stock is 19.85%.
- Is Agilent Technologies, Inc.'s return on equity (ROE) high or low?
- Agilent Technologies, Inc.'s return on equity (ROE) of 19.85% is in line with its 5-year average of 20.54%, around the middle of its 5-year range (14.75%–23.64%).
- What is the TTM average return on equity (ROE) for Agilent Technologies, Inc. (A)?
- The TTM average return on equity (ROE) for A stock is 20.59%.
- What is the 3Y average return on equity (ROE) for Agilent Technologies, Inc. (A)?
- The 3Y average return on equity (ROE) for A stock is 21.51%.
- What is the 5Y average return on equity (ROE) for Agilent Technologies, Inc. (A)?
- The 5Y average return on equity (ROE) for A stock is 20.54%.
- What is the 10Y average return on equity (ROE) for Agilent Technologies, Inc. (A)?
- The 10Y average return on equity (ROE) for A stock is 17.03%.
- What is the 15Y average return on equity (ROE) for Agilent Technologies, Inc. (A)?
- The 15Y average return on equity (ROE) for A stock is 17.40%.
- What is the 20Y average return on equity (ROE) for Agilent Technologies, Inc. (A)?
- The 20Y average return on equity (ROE) for A stock is 19.91%.
Agilent Technologies, Inc. Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-10-31 | 19.33% |
| 2024-10-31 | 21.85% |
| 2023-10-31 | 21.21% |
| 2022-10-31 | 23.64% |
| 2021-10-31 | 22.45% |
| 2020-10-31 | 14.75% |
| 2019-10-31 | 22.56% |
| 2018-10-31 | 6.92% |
| 2017-10-31 | 14.17% |
| 2016-10-31 | 10.85% |
| 2015-10-31 | 9.65% |
| 2014-10-31 | 10.36% |
| 2013-10-31 | 13.70% |
| 2012-10-31 | 22.25% |
| 2011-10-31 | 23.49% |
| 2010-10-31 | 21.19% |
| 2009-10-31 | -1.24% |
| 2008-10-31 | 27.08% |
| 2007-10-31 | 19.73% |
| 2006-10-31 | 90.65% |
| 2005-10-31 | 3.46% |
| 2004-10-31 | 10.34% |
| 2003-10-31 | -72.88% |
| 2002-10-31 | -22.30% |
| 2001-10-31 | 2.97% |
| 2000-10-31 | 14.38% |
| 1999-10-31 | 15.14% |
| 1998-10-31 | 8.50% |
Related Metrics
About Agilent Technologies, Inc.
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Padraig McDonnell